Analysts are quite bullish about these beaten-down stocks.
The company scored a $1 billion upfront payment for expanding a commercial partnership.
These stocks could give investors the best of both worlds: dividend income and the potential to earn a great profit.
The headline numbers for Royalty Pharma (RPRX) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates...
Royalty Pharma (RPRX) delivered earnings and revenue surprises of 21.21% and 23.65%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Royalty Pharma (RPRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Owl Rock Capital Corporation (ORCC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Royalty Pharma (RPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MVB Financial (MVBF) delivered earnings and revenue surprises of -65.52% and 12.83%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
PRA Group (PRAA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.